Psilocybin for Treatment-Resistant Depression in Autism with Pre-Post Brain and Cognitive Measurement to Understand Mechanisms
NCT06731621
Recruiting
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Treatment Resistant Depression, Autism Spectrum Disorder
Register for Updates
Therapeutic Effects of Electrical Vestibular Stimulation (EVS) on Balance and Gait
NCT06846047
Recruiting
The aim of the study to is determine the safety, feasibility, efficacy, and persistence of non-invasive EVS to improve balance and gait performance in healthy individuals across the lifespan. Specifically, our objective is to measure balance and gait performance before, during and after exposure to single sessions and across repeated sequences of EVS at multiple study partner sites.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/20/2025
Locations: Caring Hands Caregivers, Cupertino, California +3 locations
Conditions: Vestibulopathy
Register for Updates
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195
Recruiting
This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
02/20/2025
Locations: SCRI at the Children's Hospital at TriStar Centennial, Nashville, Tennessee +5 locations
Conditions: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Register for Updates
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
NCT05955924
Recruiting
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical. Nicotinamide is a form of Vitamin B3 that... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Calgary, Calgary, Alberta +6 locations
Conditions: Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma
Register for Updates
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
NCT06093126
Recruiting
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines and other sedatives (e.g., zolpidem, zopiclone) have been widely used to help treat insomnia. However, sleeping aids are also known to cause adverse drug reactions such as drowsiness and dizziness, that increases the risk of falls, driving impairment, visual impairment, cognitive impairment, and up... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/20/2025
Locations: Nova Scotia Health, Halifax, Nova Scotia
Conditions: Insomnia, Dementia, Frontotemporal Dementia
Register for Updates
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706
Recruiting
Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical sym... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2025
Locations: TLC Clinical Research Inc - Los Angeles, Los Angeles, California +72 locations
Conditions: Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
Register for Updates
Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
NCT06316778
Recruiting
Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystem manifestations. DM1 can affect the urinary system through the impact of the pelvic floor muscles (PFM). Urinary incontinence can occur in this situation and is often offset with compensatory measures without restoring the PFM function (e.g. sanitary pads). PFM training have already been shown to be effective in reducing or even eliminating urinary incontinence in the general population. However, no study has... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Clinique des maladies neuromusculaires, Jonquière, Quebec
Conditions: Myotonic Dystrophy Type 1, Urinary Incontinence
Register for Updates
Promoting Physical Activity Following Dysvascular Amputation
NCT06667739
Recruiting
Loss of a lower limb due to diabetes can have a devastating impact on physical and mental health and quality of life. Individuals are at risk of other diseases such as cardiovascular disease, loss of the other limb and death. Physical activity can reduce risk of chronic disease and improve health outcomes; however, physical activity levels in people with limb loss are low, often due to reduced balance and walking ability. Rehabilitation services are not readily available and the cost of deliveri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: West Park Healthcare Centre, Toronto, Ontario
Conditions: Amputation, Lower Limb Amputation Knee
Register for Updates
SCORE! ACTIVE Trial
NCT06844786
Recruiting
Hamilton is a city with a growing newcomer population. Families who are new to Canada do not always have the same resources to access healthy active living (HAL) activities as compared to Canadian-born families. The SCORE! ACTIVE trial will recruit newcomer families with young children in Hamilton and help provide them with access to HAL activities. Through this, the investigators want to see if newcomer children's perspectives of physical activity will change over time. They will also see if in... Read More
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
02/19/2025
Locations: McMaster University, Hamilton, Ontario
Conditions: Chronic Disease, Childhood Obesity
Register for Updates
Study of Olutasidenib and Temozolomide in HGG
NCT06161974
Recruiting
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
02/19/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +17 locations
Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Register for Updates
Microbiome and Diet in Parkinson's Disease
NCT06207136
Recruiting
The goal of this pilot study is to examine the feasibility and effects of an 18-month intervention diet compared to an active control diet (standard diet) in those living with Parkinson's Disease (PD), without dementia. Research has shown that eating components of Mediterranean diets are associated with a 30% lower risk to develop PD and a 40% lower mortality rate in those living with PD. Diet may influence the gut and microbiomes, thus may affect PD risk and progression. This study will exami... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
02/19/2025
Locations: UBC Pacific Parkinson's Research Centre, Vancouver, British Columbia
Conditions: Parkinson Disease, Diet, Healthy, Gut Microbiome, Gastrointestinal Microbiome
Register for Updates
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
NCT06208657
Recruiting
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
02/19/2025
Locations: John Hunter Children's Hospital, Newcastle, New South Wales +10 locations
Conditions: Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
Register for Updates